A single intravenous gene therapy extended lifespan up to threefold in cats with Sandhoff disease, a fatal inherited disorder of childhood — a promising early signal for a condition that today has no cure.

Understanding the disease

Sandhoff disease belongs to a family of conditions called lysosomal storage disorders. Lysosomes are the cell’s recycling centers, using enzymes to break down cellular waste. In Sandhoff disease, a missing enzyme — β-hexosaminidase — lets a fatty molecule called GM2 ganglioside pile up to toxic levels inside nerve cells. The buildup steadily poisons the nervous system, causing progressive loss of motor skills, seizures and, ultimately, death. Untreated children typically die around age four. It is closely related to the better-known Tay-Sachs disease, which involves the same toxic buildup through a different genetic route.

What the researchers did

A team including researchers at Auburn University delivered an adeno-associated virus (AAV) — a hollowed-out, harmless virus repurposed as a delivery vehicle — carrying working copies of both genes needed to rebuild the enzyme (HEXA and HEXB). Crucially, they gave it as a simple intravenous infusion. Earlier gene-therapy attempts for this disease required injecting directly into the brain or spinal fluid, an invasive approach; this study is the first to test an IV route in this model, which would be far easier to administer if it works in people.

The results

The benefit was dose-dependent. Untreated cats lived about 4.3 months; low-dose animals reached roughly 8.3 months, and high-dose animals about 12.4 months — a doubling to tripling of survival. High-dose cats also showed fewer tremors, less damage in the central nervous system, and improved liver function. The findings were published in Science Translational Medicine, and the authors concluded the results “support potential for translation to patients.”

Why it matters — and the caveats

For rare, fatal childhood diseases, even incremental progress carries enormous weight for the handful of families affected, who often have no options at all. A one-time therapy delivered through a vein rather than the brain would be a meaningful practical advance. But this remains animal research: cats are a valuable model for this disease, yet results in animals frequently fail to hold up in humans, and gene therapies raise their own long-term safety and durability questions. The next hurdle — human clinical trials — is where most experimental therapies stumble. Not medical advice.